Vaxart Encourages All Stockholders of Record as of April 28, 2023 to Vote by June 25, 2023, at 11:59 p.m. ET
21. Juni 2023 16:30 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today encourages its stockholders of record on April 28, 2023, to vote on its proxy if they have not yet...
Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common Stock
07. Juni 2023 09:16 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the pricing of its underwritten public offering of 16,000,000 shares of its common stock,...
Vaxart, Inc. Announces Proposed Public Offering of Common Stock
06. Juni 2023 16:01 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., June 06, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has commenced an underwritten public offering of its common stock. In addition,...
Vaxart Announces Last Subject Dosed in Phase 2 Trial of its Bivalent Norovirus Candidate, and All Subjects Challenged in Phase 2 Challenge Study of Monovalent Norovirus Candidate
06. Juni 2023 08:00 ET
|
Vaxart, Inc.
No Vaccine Related Serious Adverse Events (SAEs) reported to date On track to report topline data from two Phase 2 norovirus vaccine studies over the next 3 months SOUTH SAN FRANCISCO, Calif., June ...
Vaxart Launches New Investor Communication Program, First Event Scheduled for June 15 at 11 a.m. ET
31. Mai 2023 08:00 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it is launching an investor communication program that will give investors the ability to...
Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results
04. Mai 2023 16:01 ET
|
Vaxart, Inc.
On track to report key top line data from two Phase 2 norovirus vaccine studies mid-year and in Q3 2023 Continue to anticipate cash runway into Q2 2024 Conference call today at 4:30 p.m. ET SOUTH...
Vaxart to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4
28. April 2023 08:00 ET
|
Vaxart, Inc.
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report...
Vaxart to Present at World Vaccine Congress Washington 2023 on April 5-6
29. März 2023 08:00 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings,...
Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus
17. März 2023 08:00 ET
|
Vaxart, Inc.
Company to provide a detailed overview of its norovirus clinical program Webcast to be held on March 28, 2023 at 1:00 p.m. ET SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) --...
Vaxart Provides Business Update and Full Year 2022 Financial Results
15. März 2023 16:01 ET
|
Vaxart, Inc.
Prioritizing oral bivalent norovirus candidate, one of the most advanced norovirus vaccines in development Will continue preclinical development of novel COVID-19 vaccine constructs to enhance...